Burning Rock’s Liquid Biopsy Assay Achieved Strong Performance in the FDA-led SEQC2 Study, with Results Published on Nature Biotechnology

Go back to Burning Rock’s Liquid Biopsy Assay Achieved Strong Performance in the FDA-led SEQC2 Study, with Results Published on Nature Biotechnology
(NASDAQ: BNR) Delayed: 29.67 +0.37 (1.26%)
Previous Close $29.30    52 Week High
Open $29.41    52 Week Low
Day High $29.77    P/E N/A 
Day Low $28.57    EPS
Volume 181,679